Context Therapeutics to Present at the Jefferies Global Healthcare Conference

Context Therapeutics (Nasdaq:CNTX) will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 7:35 a.m. ET, with a live webcast and 90-day replay on its investor website.

Rhea-AI Summary

Context Therapeutics (Nasdaq:CNTX) will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 7:35 a.m. ET, with a live webcast and 90-day replay on its investor website.

Context also granted a Nasdaq Rule 5635(c)(4) inducement stock option for 146,000 shares to a new employee, priced at $2.63 per share, with a 10-year term and four-year vesting schedule.

Argus May 27 session

+13.31% close to close Open Argus

Details

News Market Reaction – CNTX

In the May 27 session, CNTX gained 13.31%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +13.3% in the session following this news. A strong positive reaction aligns with a...

Analysis

The stock surged +13.3% in the session following this news. A strong positive reaction aligns with a backdrop of improving technicals, with CNTX trading above its 200-day MA at $2.65. The news itself centers on a conference appearance and a standard inducement option grant for 146,000 shares at $2.63, which is typically neutral. Investors have recently responded well to clinical and financial milestones, so any outsized move could reflect enthusiasm for the broader 2026 catalyst path rather than this administrative update alone.

Key Figures

Inducement option size: 146,000 shares Option exercise price: $2.63 per share Option term: 10 years +5 more

Inducement option size

146,000 shares

Non-qualified stock option grant to new employee

Option exercise price

$2.63 per share

Closing price on May 26, 2026 grant date

Option term

10 years

Duration of inducement stock option

Vesting period

4 years

Employee option vesting schedule duration

Vesting cliff

1/4 after 1 year

Initial vesting on first anniversary of grant date

Subsequent vesting

36 monthly installments

Remaining option vesting cadence after first year

Webcast replay period

90 days

Duration replays remain available on company website

Conference time

7:35 a.m. ET, June 3, 2026

Jefferies Global Healthcare Conference presentation slot

Historical Context

5 past events · Latest: May 18

5 events

1. May 18

   License amendment

   24h Move

   -0.5%

   CT-202 license made fully paid-up and royalty-free via fixed payments.

2. May 06

   Earnings update

   24h Move

   -3.3%

   Q1 2026 financials with cash runway into mid-2027 and trial timelines.

3. Apr 08

   Board linkage news

   24h Move

   +0.8%

   Neogen executive appointment highlighting overlap with CNTX’s board.

4. Apr 02

   Regulatory milestone

   24h Move

   +2.6%

   FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.

5. Mar 23

   Full-year earnings

   24h Move

   +5.3%

   Full-year 2025 results emphasizing cash position and 2026 data catalysts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

t cell engaging bispecific antibodies, non-qualified stock option, nasdaq listing rule 5635(c)(4)

3 terms

t cell engaging bispecific antibodies medical

"a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors"

Engineered immune proteins that simultaneously attach to a T cell and a marker on a diseased cell, physically bringing the immune cell and its target together so the T cell can attack and kill the diseased cell. Investors care because these drugs can deliver highly targeted treatments with strong upside if safe and effective, but their clinical results, side‑effect risks and complex manufacturing make trial outcomes and approvals key drivers of a company’s value.

non-qualified stock option financial

"it has granted a non-qualified stock option award to purchase 146,000 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its presentation at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 7:35 a.m. ET.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at https://ir.contexttherapeutics.com. Replays will be available on the website for 90 days.

For additional information or to request a meeting with members of Context’s management team during these events, please contact your conference representative or IR@contexttherapeutics.com.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context also announced today that it has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option award was granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted to a new employee on their hire date (May 26, 2026) with an exercise price equal to the closing price of Context’s common stock as reported by Nasdaq on the grant date ($2.63 per share).

The stock options have a 10-year term and vest over four years, with one-fourth of the shares underlying the stock options vesting on the first anniversary of the grant date and the remainder vesting in thirty-six equal monthly installments thereafter. Vesting of the stock options is subject to continued service with Context through the applicable vesting date.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s strategy, future operations, prospects, and plans and objectives of management, are forward-looking statements. These statements may be identified by words such as “may,” “will,” “expect,” “believe,” “could,” “estimate,” “potential,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions.

Forward-looking statements in this press release include, without limitation, statements regarding (i) the ability of the Company and its employees to participate in and present at conferences; and (ii) other non-historical statements.

These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied, and the Company cannot assure that its plans, intentions, expectations, or strategies will be achieved. These risks and uncertainties include, without limitation: (i) uncertainties regarding the Company’s expectations, projections, and estimates of future costs and expenses, capital requirements, the availability of additional financing and the Company’s capital requirements; (ii) the timing, progress, and results of the Company’s discovery, preclinical and clinical development activities; (iii) clinical trial site activation and enrollment; (iv) unexpected safety or efficacy data observed during preclinical studies or clinical trials; (v) the risk that results from nonclinical or clinical studies may not be predictive of future results, and that interim data are subject to further analysis; (vi) uncertainties related to the regulatory approval process; (vii) the Company’s reliance on third parties; (viii) macroeconomic conditions; and (ix) whether the Company has sufficient funding to meet future operating expenses and capital expenditure requirements. Additional factors that may cause actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including future reports.

Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, which speak only as of the date of this press release, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Context Therapeutics (NASDAQ:CNTX) present at the Jefferies Global Healthcare Conference 2026?

Context Therapeutics is scheduled to present on June 3, 2026, at 7:35 a.m. ET. According to Context, the session takes place in New York and targets investors following its T cell engaging bispecific antibody programs for solid tumors.

How can investors watch Context Therapeutics’ Jefferies Global Healthcare Conference 2026 presentation?

Investors can watch via a live webcast on Context’s News and Events webpage. According to Context, a replay of the Jefferies Global Healthcare Conference presentation will remain available on its investor relations site for 90 days after the event.

What inducement stock option grant did Context Therapeutics (CNTX) announce on May 27, 2026?

Context announced a non-qualified stock option to purchase 146,000 shares for a new employee. According to Context, the grant is an inducement award under Nasdaq Rule 5635(c)(4), issued outside its 2021 Long-Term Performance Incentive Plan.

What are the key terms of the new Context Therapeutics inducement stock options?

The inducement options cover 146,000 shares at an exercise price of $2.63 per share. According to Context, they have a 10-year term and vest over four years, subject to the employee’s continued service through each vesting date.

How does the Context Therapeutics (CNTX) inducement grant vest over time?

The grant vests 25% on the first anniversary of the May 26, 2026 grant date. According to Context, the remaining shares vest in 36 equal monthly installments, contingent on continued service with the company.